JP2024525805A5 - - Google Patents
Info
- Publication number
- JP2024525805A5 JP2024525805A5 JP2024502082A JP2024502082A JP2024525805A5 JP 2024525805 A5 JP2024525805 A5 JP 2024525805A5 JP 2024502082 A JP2024502082 A JP 2024502082A JP 2024502082 A JP2024502082 A JP 2024502082A JP 2024525805 A5 JP2024525805 A5 JP 2024525805A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- composition according
- pharmaceutically acceptable
- acceptable salt
- visual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221329P | 2021-07-13 | 2021-07-13 | |
| US63/221,329 | 2021-07-13 | ||
| US202263336896P | 2022-04-29 | 2022-04-29 | |
| US63/336,896 | 2022-04-29 | ||
| PCT/US2022/036830 WO2023287794A2 (en) | 2021-07-13 | 2022-07-12 | Methods and compositions for improving visual function in ocular diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525805A JP2024525805A (ja) | 2024-07-12 |
| JP2024525805A5 true JP2024525805A5 (cg-RX-API-DMAC7.html) | 2025-07-17 |
Family
ID=84919637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024502082A Pending JP2024525805A (ja) | 2021-07-13 | 2022-07-12 | 眼の疾患および障害における視機能を改善するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20240299488A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4370208A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024525805A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022311780A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023287794A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010102052A2 (en) * | 2009-03-03 | 2010-09-10 | The Regents Of The University Of Michigan | Methods of inhibiting photoreceptor apoptosis |
| US10508134B2 (en) * | 2015-05-01 | 2019-12-17 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
-
2022
- 2022-07-12 AU AU2022311780A patent/AU2022311780A1/en active Pending
- 2022-07-12 JP JP2024502082A patent/JP2024525805A/ja active Pending
- 2022-07-12 US US18/578,663 patent/US20240299488A1/en active Pending
- 2022-07-12 WO PCT/US2022/036830 patent/WO2023287794A2/en not_active Ceased
- 2022-07-12 EP EP22842760.5A patent/EP4370208A4/en active Pending
-
2024
- 2024-01-11 US US18/410,820 patent/US20240197815A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hamacher et al. | Efficacy and safety levels of preserved and preservative‐free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis | |
| US20130190278A1 (en) | Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases | |
| JP7730816B2 (ja) | 過剰血管新生に関連する眼疾患を治療する化合物 | |
| US11918577B2 (en) | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases | |
| US10413529B2 (en) | Methods of inhibiting cataracts and presbyopia | |
| JP6771698B1 (ja) | ウルソデオキシコール酸を含有する老視の治療または予防剤 | |
| JP7474706B2 (ja) | ４－フェニル酪酸を含有する老視の治療または予防剤 | |
| US20210299219A1 (en) | Compositions and methods for prevention and treatment of corneal haze and scarring | |
| US20190298674A1 (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders | |
| US10736863B2 (en) | Methods of inhibiting cataracts and presbyopia | |
| CN114929245A (zh) | 用于治疗干性年龄相关性黄斑变性(amd)或继发于干性amd的地图样萎缩的抗c5剂 | |
| JP2024525805A5 (cg-RX-API-DMAC7.html) | ||
| KR20170123502A (ko) | 콜라겐 및 색소 상피성 인자를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 | |
| KR102293398B1 (ko) | Si를 이용한 망막 변성 개 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델 | |
| JP2014510115A (ja) | 初期の緑内障における正常な視覚機能を回復するｐａｃａｐ（下垂体アデニル酸シクラーゼ活性化ポリペプチド）に基づく眼科用製剤 | |
| CN117731662A (zh) | 一种胆碱能受体拮抗剂在预防近视中的应用及制备方法 | |
| WO2025036488A9 (en) | Methods of treating age-related macular degeneration and diabetic macular edema | |
| US20030166544A1 (en) | Use of ADNP for the treatment of glaucomatous optic neuropathy | |
| US20250134849A1 (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin | |
| HK40114204A (zh) | 通过靶向过氧化物酶体增殖物激活受体(ppar)信号通路治疗屈光性疾病 | |
| CN118873659A (zh) | 通过靶向过氧化物酶体增殖物激活受体(ppar)信号通路治疗屈光性疾病 | |
| TW202529793A (zh) | 生長激素抑制劑的用途、和含有生長激素抑制劑的藥物組合物、製劑、及其裝置 | |
| JP2026505378A (ja) | 視覚を改善するためのα２アドレナリン作動薬 | |
| FRACO et al. | A REVIEW OF LEISKE STYLE SEMI‐FLEXIBLE INTRAOCULAR LENSES 1981–1984 | |
| JP2007182435A (ja) | 角結膜障害治療剤 |